Brain Cancer
Irinotecan plus BCNU shows low toxicity in patients with progressive glioma
Published in Cancer Weekly, May 25th, 2004
According to published research from the United States, "irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma (MG). We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chlorocthyl)-1-nitrosourea, for patients with recurrent or progressive MG. Irinotecan dose escalation occurred independently within 2 strata: patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) and patients not receiving EIAEDs.
"BCNU was administered at a dose of 100 mg/m2 over 1 hour every 6 weeks on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-05-25)
More Articles from Cancer Weekly
- Acute Myeloid Leukemia
A combined regimen is active against refractory acute myelogenous leukemia - Cancer Risk Factor
Nitrites consumed from animal products may increase pancreatic cancer risk - Public Health
Drinking water wells near abandoned mines need to be tested for carcinogens - AIDS/HIV Transmission
AZT causes pattern of mutations in Tk gene of mice treated as neonates - Actinic Keratosis
Phase II clinical trial of Polyphenon E Ointment begins - Addiction Research
New study to ask: Will early lung cancer detection lead to tobacco cessation? - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
